Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain
Articolo
Data di Pubblicazione:
2011
Tipologia CRIS:
Articolo su Rivista
Elenco autori:
Banz, K; Bischoff, H; Brunner, M; Chouaid, C; Carpeno, Jd; de Marinis, F; Grossi, F; Vergnenegre, A; Walzer, S
Link alla scheda completa:
Pubblicato in: